Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice
Chang-yun Hu, … , Mark J. Shlomchik, Li Wen
Chang-yun Hu, … , Mark J. Shlomchik, Li Wen
Published December 3, 2007
Citation Information: J Clin Invest. 2007;117(12):3857-3867. https://doi.org/10.1172/JCI32405.
View: Text | PDF
Research Article Article has an altmetric score of 10

Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice

  • Text
  • PDF
Abstract

The precise roles of B cells in promoting the pathogenesis of type 1 diabetes remain undefined. Here, we demonstrate that B cell depletion in mice can prevent or delay diabetes, reverse diabetes after frank hyperglycemia, and lead to the development of cells that suppress disease. To determine the efficacy and potential mechanism of therapeutic B cell depletion, we generated a transgenic NOD mouse expressing human CD20 (hCD20) on B cells. A single cycle of treatment with an antibody specific for hCD20 temporarily depleted B cells and significantly delayed and/or reduced the onset of diabetes. Furthermore, disease established to the point of clinical hyperglycemia could be reversed in over one-third of diabetic mice. Why B cell depletion is therapeutic for a variety of autoimmune diseases is unclear, although effects on antibodies, cytokines, and antigen presentation to T cells are thought to be important. In B cell–depleted NOD mice, we identified what we believe is a novel mechanism by which B cell depletion may lead to long-term remission through expansion of Tregs and regulatory B cells. Our results demonstrate clinical efficacy even in established disease and identify mechanisms for therapeutic action that will guide design and evaluation of parallel studies in patients.

Authors

Chang-yun Hu, Daniel Rodriguez-Pinto, Wei Du, Anupama Ahuja, Octavian Henegariu, F. Susan Wong, Mark J. Shlomchik, Li Wen

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 Total
Citations: 4 10 5 8 14 8 8 7 10 4 11 14 17 16 17 23 18 7 1 202
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2015 (11)

Title and authors Publication Year
Rituximab Does Not Reset Defective Early B-Cell Tolerance Checkpoints
Chamberlain Nicolas, Christopher Massad, Tyler Oe, Tineke Cantaert, Kevan Herold, Eric Meffre
Journal of Clinical Investigation 2015
Lessons from the mouse: potential contribution of bystander lymphocyte activation by viruses to human type 1 diabetes
JA Pane, BS Coulson
Diabetologia 2015
The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes
JA Pearson, FS Wong, L Wen
Journal of Autoimmunity 2015
Thinking bedside at the bench: the NOD mouse model of T1DM
JC Reed, KC Herold
Nature Reviews Endocrinology 2015
Activatory and Inhibitory Fcγ Receptors Augment Rituximab-mediated Internalization of CD20 Independent of Signaling via the Cytoplasmic Domain
AT Vaughan, CH Chan, C Klein, MJ Glennie, SA Beers, MS Cragg
The Journal of biological chemistry 2015
Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response
DG Adlowitz, J Barnard, JN Biear, C Cistrone, T Owen, W Wang, A Palanichamy, E Ezealah, D Campbell, C Wei, RJ Looney, I Sanz, JH Anolik, O Frey
PloS one 2015
The gut microbiota and Type 1 Diabetes
E Gülden, FS Wong, L Wen
Clinical Immunology 2015
NLRP3 deficiency protects from type 1 diabetes through the regulation of chemotaxis into the pancreatic islets
C Hu, H Ding, Y Li, JA Pearson, X Zhang, RA Flavell, FS Wong, L Wen
Proceedings of the National Academy of Sciences 2015
Regulation of B lymphocyte responses to Toll-like receptor ligand binding during diabetes prevention in non-obese diabetic (NOD) mice: TLR activation of B cell regulation
CS Wilson, SK Elizer, AF Marshall, BT Stocks, DJ Moore
Journal of Diabetes 2015
A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice
RG Gill, PP Pagni, T Kupfer, CH Wasserfall, S Deng, A Posgai, Y Manenkova, AB Hani, L Straub, P Bernstein, MA Atkinson, KC Herold, M Herrath, T Staeva, MR Ehlers, GT Nepom
Diabetes 2015
Targeting Anti-Insulin B Cell Receptors Improves Receptor Editing in Type 1 Diabetes-Prone Mice
RH Bonami, JW Thomas
Journal of immunology (Baltimore, Md. : 1950) 2015

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 14 patents
Highlighted by 1 platforms
129 readers on Mendeley
1 readers on CiteULike
See more details